# Gozellix (gallium ga-68 gozetotide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gallium-ga-68-gozetotide

> The FDA approved Gozellix (gallium ga-68 gozetotide), sponsored by Telix Pharmaceuticals Ltd (TLX), on March 20, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Gozellix (gallium ga-68 gozetotide) |
| Codes |  |
| Sponsor | Telix Pharmaceuticals Ltd (TLX) https://sec-api.dev/companies/tlx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 17, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214032 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name TELIX; product ILLUCCIX (GALLIUM GA-68 GOZETOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214032%22

### March 23, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215841 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name NOVARTIS; product LOCAMETZ (GALLIUM GA-68 GOZETOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215841%22

### March 15, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214032 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230315, review_priority STANDARD; sponsor_name TELIX; product ILLUCCIX (GALLIUM GA-68 GOZETOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214032%22

### March 20, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA219592 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250320, review_priority STANDARD; sponsor_name TELIX INNOVATIONS; product GOZELLIX (GALLIUM GA-68 GOZETOTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219592%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gallium-ga-68-gozetotide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Gozellix (gallium ga-68 gozetotide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gallium-ga-68-gozetotide

```bibtex
@misc{secapidev_pdufa_gallium_ga_68_gozetotide_20261116,
  title        = {Gozellix (gallium ga-68 gozetotide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gallium-ga-68-gozetotide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gallium_ga_68_gozetotide_20261116","title":"Gozellix (gallium ga-68 gozetotide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gallium-ga-68-gozetotide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
